Efficient in vivo priming by vaccination with recombinant NY-ESO-1 protein and CpG in antigen naïve prostate cancer patients

Clinical Cancer Research

Volumn 17, Issue 4, 2011, Pages 861-870

  Karbach, Julia ^a   Neumann, Antje ^a   Atmaca, Akin ^a   Wahle, Claudia ^a   Brand, Kathrin ^a   Von Boehmer, Lotta ^b   Knuth, Alexander ^b   Bender, Armin ^c   Ritter, Gerd ^d   Old, Lloyd J ^d   Jäger, Elke ^a  

^a KRANKENHAUS NORDWEST   (Germany)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c UNIVERSITY HOSPITAL MARBURG   (Germany)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGATOLIMOD; ANTIBODY; RECOMBINANT ANTIGEN; RECOMBINANT NY ESO 1 PROTEIN; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ANTIBODY TITER; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ARTICLE; B LYMPHOCYTE; BLISTER; CANCER IMMUNIZATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CLONE; DRUG EFFECT; DRUG SAFETY; EPITOPE MAPPING; HLA MATCHING; HUMAN; HUMORAL IMMUNITY; HYPERSENSITIVITY REACTION; HYPOTENSION; IN VIVO STUDY; INJECTION SITE ERYTHEMA; INJECTION SITE NECROSIS; INJECTION SITE PRURITUS; MALE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; RASH; SWELLING; TUMOR CELL LINE;

EID: 79951849234     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-1811     Document Type: Article

References (42)

1. Chen YT, Scanlan MJ, Sahin U, et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci U S A 1997;94:1914-18. (Pubitemid 27113936)
2. Jungbluth AA, Chen YT, Stockert E, et al. Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues. Int J Cancer 2001;92:856-60. (Pubitemid 32467376)
3. Scanlan MJ, Gure AO, Jungbluth AA, Old LJ, Chen YT. Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol Rev 2002;188:22-32. (Pubitemid 35398862)
4. Gnjatic S, Nishikawa H, Jungbluth AA, et al. NY-ESO-1: review of an immunogenic tumor antigen. Adv Cancer Res 2006;95:1-30. (Pubitemid 44088423)
5. Stockert E, Jäger E, Chen YT, et al. A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J Exp Med 1998;187:1349-54. (Pubitemid 28189124)
6. J̈ager E, Chen YT, Drijfhout JW, et al. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J Exp Med 1998;187: 265-70. (Pubitemid 28060443)
7. Jäger E, Stockert E, Zidianakis Z, et al. Humoral immune responses of cancer patients against Cancer-Testis" antigen NY-ESO-1: correlation with clinical events. Int J Cancer 1999;84:506-10.
8. Jäger E, Nagata Y, Gnjatic S, et al. Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses. Proc Natl Acad Sci U S A 2000;97:4760-5. (Pubitemid 30238631)
9. Gnjatic S, Atanackovic D, Jäger E, et al. Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: correlation with antibody responses. Proc Natl Acad Sci USA 2003; 100:8862-67. (Pubitemid 36899189)
10. Jäger E, Jäger D, Karbach J, et al. Identification of NY-ESO-1 epitopes presented by human histocompatibility antigen (HLA)-DRB4*0101- 0103 and recognized by CD4+ T lymphocytes of patients with NY-ESO-1-expressing melanoma. J Exp Med 2000;191:625-30.
11. Jager E, Gnjatic S, Nagata Y, et al. Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1 +cancers. Proc Natl Acad Sci U S A 2000;97:12198-203.
12. Old LJ. Cancer vaccines: an overview. Cancer Immun 2008;8 Suppl 1:1.
13. Caballero OL, Yao YT. Cancer/testis (CT) antigens: Potential targets for immunotherapy. Cancer Sci 2009;100:2014-2021
14. Jäger E, Karbach J, Gnjatic S, et al. Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients. Proc Natl Acad Sci U S A 2006;103:14453-8. (Pubitemid 44484771)
15. Karbach J, Gnjatic S, Bender A, et al. Tumor-reactive CD8+ T-cell responses after vaccination with NY-ESO-1 peptide, CpG 7909 and Montanide ISA-51: association with survival. Int J Cancer 2010;126:909-18.
16. Davis ID, Chen W, Jackson H, et al. Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans. Proc Natl Acad Sci U S A 2004;101:10697-702. (Pubitemid 38955805)
17. Kruit WH, van Ojik HH, Brichard VG, et al. Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanoma. Int J Cancer 2005; 117: 596-604. (Pubitemid 41504547)
18. Atanackovic D, Altorki NK, Stockert E, et al. Vaccine-induced CD4+ T cell responses to MAGE-3 protein in lung cancer patients. J. Immunol 2004;172:3289-96. (Pubitemid 38263721)
19. Krieg AM. CpG motifs: the active ingredient in bacterial extracts?Nat Med 2003;9:831-5.
20. Bendigs S, Salzer U, Lipford GB, Wagner H, Heeg K. CpG- oligodeoxynucleotides co-stimulate primary T cells in the absence of antigen-presenting cells. Eur J Immunol 1999;29:1209-18. (Pubitemid 29164167)
21. Hartmann G, Weiner GJ, Krieg AM. CpG DNA: a potent signal for growth, activation, and maturation of human dendritic cells. Proc Natl Acad Sci U S A 1999;96:9305-10. (Pubitemid 29374750)
22. Hemmi H, Takeuchi O, Kawai T, et al. Toll-like receptor recognizes bacterial DNA. Nature 2000;408:740-5. (Pubitemid 32015992)
23. Krieg AM, Yi AK, Matson S, et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995;374:546-9.
24. Oxenius A, Martinic MM, Hengartner H, Klenerman P. CpG-containing oligonucleotides are efficient adjuvants for induction of protective antiviral immune responses with T-cell peptide vaccines. J Virol 1999;73:4120-6. (Pubitemid 29189857)
25. Weiner GJ, Liu HM, Wooldridge JE, Dahle CE, Krieg AM. Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. Proc Natl Acad Sci U S A 1997;94:10833-7.
26. Jäger E, Stockert E, Zidianakis Z, et al. Humoral immune responses of cancer patients against "Cancer-Testis" antigen NY-ESO-1: correlation with clinical events. Int J Cancer 1999;84:506-10.
27. Odunsi K, Jungbluth AA, Stockert E, et al. NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer. Cancer Res 2003;63:6076-83. (Pubitemid 37187513)
28. Nakada T, Noguchi Y, Satoh S, et al. NY-ESO-1 mRNA expression and immunogenicity in advanced prostate cancer. Cancer Immun 2003;3:10.
29. Fossa A, Berner A, Fossa SD, Hernes E, Gaudernack G, Smeland EB. NY-ESO-1 protein expression and humoral immune responses in prostate cancer. Prostate 2004;59:440-28.
30. Gnjatic S, Nagata Y, Jager E, et al. Strategy for monitoring T cell responses to NY-ESO-1 in patients with any HLA class I allele. Proc Natl Acad Sci U S A 2000;97:10917-22.
31. Knuth A, Danowski B, Oettgen HF, Old LJ (1984) T-cell-mediated cytotoxicity against autologous malignant melanoma: analysis with interleukin-2-dependent T-cell cultures. Proc Natl Acad Sci U S A 1984; 81:3511-15. (Pubitemid 14122704)
32. Adams S, O'Neill DW, Nonaka D, et al. Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant. J Immunol 2008;181:776-84.
33. Kawabata R, Wada H, Isobe M, et al. Antibody response against NY-ESO-1 in CHP-NY-ESO-1 vaccinated patients. Int J Cancer 2007;120:2178-84. (Pubitemid 46555855)
34. Valmori D, Souleimanian NE, Tosello V, et al. Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming. Proc Natl Acad Sci U S A 2007;104:8947-52. (Pubitemid 47175417)
35. Jager E, Ringhoffer M, Dienes HP, et al. Granulocyte-macrophage-colony- stimulating factor enhances immune responses to melanoma-associated peptides in vivo. Int J Cancer 1996;67:54-62. (Pubitemid 26236069)
36. Isobe M, Eikawa S, Uenaka A, et al. Correlation of high and decreased NY-ESO-1 immunity to spontaneous regression and subsequent recurrence in a lung cancer patient.Cancer Immun 2009;9:8.
37. Kim D, Rhee JW, Kwon S, et al. Immunostimulation and anti -DNA antibody production by backbone modiefied CpG-DNA. Biochem Biophys Res Commun 2009;379:362-7.
38. Baumgaertner P, Rufer N, Devevre E, et al. Ex vivo detectable human CD8 T-cellresponses to cancer-testis antigens. Cancer Res 2006;66:1912-6.
39. Nagata Y, Ono S, Matsuo M, et al. Differential presentation of a soluble exogenous tumor antigen, NY-ESO-1, by distinct human dendritic cell populations. Proc Natl Acad Sci U S A 2002;99:10629-34.
40. Uenaka A, Wada H, Isobe M, et al. T cell immunomonitoring and tumor responses in patients immunized with a complex of cholesterol-bearing hydrophobized pullulan (CHP) and NY-ESO-1 protein. Cancer Immun 2007;7:9.
41. Speiser DE, Lienard D, Rufer N, et al. Rapid and strong human CD8+T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest 2005;115:739-46. (Pubitemid 40322250)
42. Fourcade J, Kudela P, Andrade Filho PA, et al. Immunization with analog peptide in combination with CpG and montanide expands tumor antigen-specific CD8+ T cells in melanoma patients. J Immunother 2008;31:781-91.